Human UMP/CMP kinase plays a crucial role in supplying precursors for nucleic acid synthesis by catalyzing the conversion of UMP, CMP, and dCMP into their diphosphate form. In addition, this kinase is an essential component of the activation cascade of medicinally relevant nucleoside analog prodrugs such as AraC, gemcitabine, and ddC. During the catalytic cycle the enzyme undergoes large conformational changes from open in the absence of substrates to closed in the presence of both phosphoryl donor and phosphoryl acceptor. Here we report the crystal structure of the substrate-free, open form of human UMP/CMP kinase. Comparison of the open structure with the closed state previously reported for the similar Dictyostelium discoideum UMP/CMP kinase reveals the conformational changes that occur upon substrate binding. We observe a classic example of induced fit where substrate-induced conformational changes in hinge residues result in rigid body movements of functional domains to form the catalytically competent state. In addition, a homology model of the human enzyme in the closed state based on the structure of D. discoideum UMP/CMP kinase aids to rationalize the substrate specificity of the human enzyme.UMP/CMP kinase plays a critical role in the pathway that supplies nucleotide precursors for DNA and RNA synthesis. The physiological substrates UMP, CMP, and dCMP are reversibly converted by UMP/CMP kinase into their diphosphate form according to the following reaction scheme.Subsequent phosphorylation by nucleoside diphosphate kinase results in the triphosphorylated form of these nucleotides, which are the substrates for DNA and RNA polymerases. Additionally, UMP/CMP kinase participates in the activation of clinically relevant nucleoside analog prodrugs that are used in cancer and viral chemotherapy. Therefore, understanding the determinants of substrate specificity, the precise roles played by its catalytic residues, and the conformational changes that take place during the catalytic cycle is of paramount importance for the development of more effective anti-cancer and anti-viral agents.Despite the physiological and medicinal importance of this enzyme, the human form was cloned only in 1999 (1). This work was followed by biochemical characterization of the enzyme, which revealed its ability to phosphorylate synthetic nucleosides (2-4). Important examples are the monophosphate form of the cytidine analogs 1--D-arabinofuranosylcytosine (AraC) 1 and 2Ј,2Ј-difluorodeoxycytidine (gemcitabine), a mainstay of leukemia and lymphoma therapy. The first step in the conversion of these cytidine analogs to their pharmacologically active triphosphorylated form is catalyzed by deoxycytidine kinase. We have recently published the structure of human deoxycytidine kinase in complex with AraC, gemcitabine, and its physiological substrate deoxycytidine (5). The second step of AraC and gemcitabine activation, from the monophosphate to the diphosphate form, is catalyzed by UMP/CMP kinase. The third phosphate group is added by the non...